We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
-1.86%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$14.7B
AUM Growth
-$908M
Cap. Flow
-$379M
Cap. Flow %
-2.57%
Top 10 Hldgs %
84.38%
Holding
107
New
11
Increased
15
Reduced
16
Closed
4

Top Buys

Rank Stock Value
1
BCEL
Atreca, Inc. Class A Common Stock
BCEL
+$63.8M
2
ADPT icon
Adaptive Biotechnologies
ADPT
+$51.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$26M
4
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$22.4M
5
HRTX icon
Heron Therapeutics
HRTX
+$20M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$184M
2
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$97.2M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$69.5M
4
GHDX
Genomic Health, Inc.
GHDX
+$55.6M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$38.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.62%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BOLD
26
DELISTED
Audentes Therapeutics, Inc
BOLD
$57M 0.39%
1,506,438
-208,745
-12% -$8.02M
ADPT icon
27
Adaptive Biotechnologies
ADPT
$4.15B
$56.3M 0.38%
+1,165,411
New +$51.6M
BCRX icon
28
BioCryst Pharmaceuticals
BCRX
$2.44B
$54.5M 0.37%
14,382,673
-735,408
-5% -$4.43M
RARX
29
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$54.2M 0.37%
1,801,695
+978,582
+119% +$22.4M
MYOK
30
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$51M 0.35%
1,016,306
– –
DBVT
31
DBV Technologies
DBVT
$914M
$45.3M 0.31%
550,956
– –
KRYS icon
32
Krystal Biotech
KRYS
$10.3B
$41.7M 0.28%
1,034,674
+250,000
+32% +$8.17M
CBAY
33
DELISTED
Cymabay Therapeutics
CBAY
$40.9M 0.28%
5,707,411
– –
QURE icon
34
uniQure
QURE
$3.36B
$40.5M 0.28%
517,700
-87,300
-14% -$5.56M
KNSA icon
35
Kiniksa Pharmaceuticals
KNSA
$6.17B
$37.9M 0.26%
2,799,577
-200,423
-7% -$3.11M
ZYME icon
36
Zymeworks
ZYME
$2.05B
$37.6M 0.26%
1,708,472
– –
NGNE icon
37
Neurogene
NGNE
$773M
$25.8M 0.18%
546,708
– –
AXSM icon
38
Axsome Therapeutics
AXSM
$10.9B
$19.9M 0.14%
772,286
-427,714
-36% -$8.57M
XNCR icon
39
Xencor
XNCR
$2.07B
$17.5M 0.12%
428,120
– –
MRUS
40
DELISTED
Merus
MRUS
$17M 0.12%
1,160,014
– –
ACOR
41
DELISTED
Acorda Therapeutics
ACOR
$15.4M 0.1%
16,760
+14,326
+589% +$17.6M
LJPC
42
DELISTED
La Jolla Pharmaceutical Company
LJPC
$14.4M 0.1%
1,559,231
+1,053,991
+209% +$7.94M
AIMT
43
DELISTED
Aimmune Therapeutics
AIMT
$14M 0.1%
673,908
– –
ACGN
44
DELISTED
Aceragen Inc
ACGN
$12.3M 0.08%
271,202
-13,782
-5% -$652K
PTGX icon
45
Protagonist Therapeutics
PTGX
$9.99B
$12.1M 0.08%
995,082
+591,189
+146% +$6.54M
MRKR icon
46
Marker Therapeutics
MRKR
$23.2M
$11.9M 0.08%
150,000
– –
SYRE icon
47
Spyre Therapeutics
SYRE
$9.39B
$11.7M 0.08%
68,544
– –
ASMB icon
48
Assembly Biosciences
ASMB
$700M
$10.8M 0.07%
66,937
+54,555
+441% +$10.4M
SGMO
49
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$10.8M 0.07%
999,823
– –
CPRX
50
DELISTED
Catalyst Pharmaceutical
CPRX
$9.83M 0.07%
2,559,461
-340,539
-12% -$1.47M
1
2
3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2019 Portfolio in Review

As of Q2 2019, Julian Baker held 107 positions worth $14.7B, down 5.8% from $15.6B the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Julian Baker's Q2 2019 filing shows 11 new, 15 increased, 16 reduced and 4 closed positions. Its largest new stake was Atreca, Inc. Class A Common Stock: 3,532,760 shares worth $66.6M. The largest sale was Incyte, an estimated $184M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Technology.

  • Julian Baker's largest Q2 2019 buy was Atreca, Inc. Class A Common Stock: 3,532,760 shares worth $66.6M.
  • Julian Baker added most to Neurocrine Biosciences in Q2 2019, an estimated $26M increase.
  • Julian Baker's biggest Q2 2019 reduction was Incyte, cutting an estimated $184M.
  • Julian Baker fully exited Clementia Pharmaceuticals Inc. in Q2 2019, selling an estimated $97.2M.
  • Julian Baker's ten largest holdings make up 84% of its $14.7B portfolio in Q2 2019.
  • Julian Baker opened 11 new positions and closed 4 in Q2 2019.
  • Julian Baker's portfolio value fell 5.8% quarter-over-quarter to $14.7B.

Based on Baker Bros. Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.